{"id":"nct:NCT04433221","kind":"trial","title":"Combination Immunotherapy Targeting Sarcomas","authors":["Shenzhen Geno-Immune Medical Institute"],"author_count":1,"year":2020,"published":"2020-06-16","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT04433221","source_url":"https://clinicaltrials.gov/study/NCT04433221","archive_url":"https://space-kitty.com/papers/nct:NCT04433221","updated":"2026-08-26","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines multiple CAR T cells followed by sarcoma vaccines.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Sarcoma","Osteoid Sarcoma","Ewing Sarcoma"],"details":{"acronym":null,"status":"NOT_YET_RECRUITING","phase":"PHASE1, PHASE2","study_type":"INTERVENTIONAL","enrollment":20,"sponsor":"Shenzhen Geno-Immune Medical Institute","conditions":["Sarcoma","Osteoid Sarcoma","Ewing Sarcoma"],"interventions":["BIOLOGICAL: Multiple sarcoma-specific CAR-T cells and sarcoma vaccines"],"start_date":"2027-07-01","start_date_type":"ESTIMATED","primary_completion_date":"2029-05-31","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}